Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) said it will use Europe’s flagship allergy and clinical immunology congress to showcase progress across its pollen and food allergy pipeline, including clinical proof-of-concept data for its VLP Peanut candidate.
The AIM-listed biotechnology company will present 15 posters and oral presentations at the European Academy of Allergy and Clinical Immunology Congress 2026, which takes place in Istanbul, Türkiye, from 12 to 15 June.
The presentations include data from the Phase I/IIa PROTECT trial of VLP Peanut, the group’s short-course peanut allergy immunotherapy candidate. Allergy Therapeutics said the trial met its primary endpoint, showing a benign safety profile and a dose-response in tolerogenic immune responses.
The company will also present blinded first-year safety data from its G308 Phase III trial of Grass MATA MPL in children with grass-induced seasonal allergic rhinitis and rhinoconjunctivitis. The data showed a benign safety profile in the first year of treatment and a low trial discontinuation rate.
Chief executive Manuel Llobet said the PROTECT data confirmed “a strong safety and tolerability profile” while demonstrating clinical proof of concept, adding that the group is continuing preparations for a Phase IIb trial. Allergy Therapeutics is a UK-headquartered commercial biotechnology company focused on allergy immunotherapies and diagnostic products.
